Skip to main content

Anti-Diabetic

Characteristics of Polyphenols of Black Hulless Barley Bran and Its Anti-Diabetic Activity


Polyphenols play a crucial role in promoting human health. This study aims to investigate the polyphenols of black hulless barley bran (HBP) and evaluate their anti-diabetic mechanisms in vivo. Using UPLC-QTOF-MS/MS, 27 compounds were identified in HBP, including four phenolic acids, 14 flavonoids, and nine anthocyanidins. High contents of Chrysoeriol 7-O-glucuronide (42.09 mg/g), Cyanidin 3-O-glucoside (21.02 mg/g), and Cyanidin 3-O-(6″-O-malonyl)-glucoside (24.45 mg/g) were quantified via UPLC in HBP. Administration of HBP significantly reduced fasting blood glucose (FBG), improved glucose intolerance and lipid profiles, and alleviated liver and pancreatic damage in type 2 diabetic (T2DM) mice. 

Furthermore, it enhanced serum antioxidant enzyme activities and modulated inflammatory cytokines. Transcriptomic analysis revealed that HBP influenced signal transduction and the immune system, particularly in key signaling pathways, including Hippo, TGF-beta, HIF-1, and p53, associated with T2DM. Although HBP had minimal impact on gut microbiota diversity and SCFA levels, it presents a promising candidate for T2DM intervention through its multifaceted mechanisms.

Hulless barley brans are typically discarded as waste or utilized as low-value animal feed. In this study, 27 polyphenols were identified in the polyphenolic composition of black hulless barley bran (HBP) using UPLC-QTOF-MS/MS. The HBP exhibited a TAC of 55.39 mg/g, a TPC of 242.336 mg/g, and a TFC of 138.8 mg/g. Furthermore, high concentrations of Chrysoeriol 7-O-glucuronide (42.09 mg/g), Cyanidin 3-O-glucoside (21.02 mg/g), and Cyanidin 3-O-(6′′-O-malonyl)-glucoside (24.45 mg/g) were quantified in HBP using UPLC.

The results from the animal tests indicate that HBP can effectively alleviate the conditions of T2DM mice induced by STZ. Specifically, it reduces FBG, lowers the liver index, improves glucose intolerance, alleviates dyslipidemia, enhances serum antioxidant capacity, reduces inflammation, and mitigates liver and pancreatic injury. However, HBP had minimal effects on regulating the diversity and abundance of the gut microbiota and SCFA.

Furthermore, analysis of the mouse hepatic transcriptome revealed that the DEGs (CM vs. NC, HDP vs. CM) were enriched in signal transduction and the immune system. More specifically, HBP administration influenced the expression of genes associated with diabetes, such as CDKN1A, CD68, C1qa, and C1qb, which are linked to signaling pathways involving Hippo, TGF-beta, HIF-1, p53, and cGMP-PKG. These findings suggest that HBP may modulate these signaling pathways to regulate blood glucose levels and insulin secretion. These findings could provide a scientific basis for the research and development of functional foods and dietary supplements derived from black hulless barley bran.

Genetics, Genomics, DNA Sequencing, Gene Therapy, CRISPR, Genetic Engineering, Human Genome, Molecular Biology, Mutation, Genetic Variation, Epigenetics, Genetic Disorders, Heredity, Biotechnology, Precision Medicine, Genetic Research, Genome Editing, RNA Biology, Genetic Mapping, Personalized Medicine,

#Genetics, #Genomics, #DNASequencing, #GeneTherapy, #CRISPR, #GeneticEngineering, #HumanGenome, #MolecularBiology, #Mutation, #GeneticVariation, #Epigenetics, #GeneticDisorders, #Heredity, #Biotechnology, #PrecisionMedicine, #GeneticResearch, #GenomeEditing, #RNABiology, #GeneticMapping, #PersonalizedMedicine

Comments

Post a Comment

Popular posts from this blog

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Post-Stroke Cardiovascular risks

Study finds genetic factors key to post-stroke cardiovascular risks In a recent study published in the journal Stroke , researchers identify genetic and molecular risk factors for subsequent cardiovascular outcomes after incident stroke in an effort to identify potential therapeutic targets to improve patient prognoses. Identifying the causes of stroke Stroke is a major global health issue that causes significant disability and mortality, particularly arterial ischemic stroke (AIS). AIS, which is a type of stroke caused by blocked blood flow to the brain, is responsible for up to 85% of stroke cases. AIS arises due to cerebral blood vessel blockage, with modifiable risk factors including hypertension, diabetes, dyslipidemia, atrial fibrillation, obesity, and lifestyle behaviors. Although genome-wide association studies (GWAS) often focus on incident strokes, studying subsequent events can provide new insights into stroke progression. Further research is crucial to identify genetic and...
Post a Comment
Read more

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more